Sarepta Therapeutics (SRPT) Long-Term Deferred Tax (2012 - 2013)
Sarepta Therapeutics (SRPT) posted quarterly Long-Term Deferred Tax of $133.6 million for Q4 2013, up 17.09% year-over-year from $114.1 million in Q4 2012, and up 17.09% quarter-over-quarter from $114.1 million in Q4 2012.
Sarepta Therapeutics (SRPT) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Sarepta Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $133.6 million for Q4 2013.
- In Q4 2013, Long-Term Deferred Tax rose 17.09% year-over-year to $133.6 million; the TTM figure through Dec 2013 stood at $133.6 million (up 17.09% YoY), while the FY2013 annual figure was $133.6 million, up 17.09% from the prior year.
- Long-Term Deferred Tax for Q4 2013 stood at $133.6 million, up from $114.1 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $133.6 million in Q4 2013, with the low at $114.1 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 133.60 Mn |
| Dec 31, 2012 | 114.10 Mn |